Chemotherapy Induced Peripheral Neuropathy Market Growth Opportunities and Forecast by 2028

[Research Report] The chemotherapy induced peripheral neuropathy market is projected to reach US$ 1,174.26 million by 2028 from US$ 813.48 million in 2021; it is expected to register a CAGR of  5.4% from 2021 to 2028.

Chemotherapy-induced peripheral neuropathy is one of the most frequent side effects caused by antineoplastic agents. Clinically, it is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, chemotherapy-induced peripheral neuropathy constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing it; moreover, the possibilities of treating this syndrome are limited.

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Chemotherapy Induced Peripheral Neuropathy Market: Strategic Insights

The report offers insights and in-depth analysis of the chemotherapy induced peripheral neuropathy (CIPN) market emphasizing market trends, technological advancements, and market dynamics. It also provides the competitive landscape analysis of leading market players across the world. Furthermore, the report includes the impact of the COVID-19 pandemic on the chemotherapy induced peripheral neuropathy market across all the regions. The pandemic has created both a public health crisis and an economic crisis worldwide. The global market for chemotherapy induced peripheral neuropathy before the pandemic was constantly growing owing to regularity of cancer screening, consultations, and treatments. The first wave of COVID-19 disrupted the consultations, follow-ups, and screenings of oncological cases. Moreover, disruptions in clinical trials and drug supply to patients during the early stage of the COVID-19 pandemic impacted the most crucial areas of the chemotherapy induced peripheral neuropathy market. A shift in focus to the prompt treatment of COVID-19 led to negligence toward various other medical conditions. In addition, the decrease in the detection of cancer cases and chemotherapy sessions for treatment hampered the demand for chemotherapy induced peripheral neuropathy diagnoses and treatments.  

Market Insights

Cancer is a leading cause of death worldwide. According to the World Health Organization (WHO), cancer was reported as the first leading cause of death in the people of age below 70 years in 183 countries and the fourth leading cause of death among the population of all ages in 123 countries worldwide in 2019. In addition, as per the data published by the WHO in March 2021, different cancer types caused ~10 million deaths in 2020.

World’s Most Prevalent Forms of Cancer, 2020

The increasing prevalence of cancer has created a burden on healthcare systems across the world, along with bolstering the demand for chemotherapy. Chemotherapy-induced peripheral neuropathy is a common adverse effect of neurotoxic anticancer drugs, such as platinum-derivative drugs (cisplatin and oxaliplatin), spindle poisons [taxanes (paclitaxel and docetaxel), vinca alkaloids, vincristine, epothilones, and eribulin], bortezomib, and thalidomide. The high prevalence of chemotherapy-induced peripheral neuropathy raises concerns about cancer patients and survivors, and their healthcare providers, especially because there is no single effective way to prevent this condition.

In a study conducted by “The Journal of the International Association for the Study of Pain,” chemotherapy-induced peripheral neuropathy prevalence was reported at 68.1% (57.7–78.4 when measured in the first month after chemotherapy, 60.0% (36.4–81.6) in the third month, and 30.0% (6.4–53.5) in the sixth month or later. Thus, the growing incidence of chemotherapy-induced peripheral neuropathy with the increasing prevalence of cancer boosts the growth of the chemotherapy-induced peripheral neuropathy market.

Drug Class-Based Insights

Based on drug class, the chemotherapy induced peripheral neuropathy market is segmented into steroids, antidepressants, anti-seizure, and narcotics. In 2021, the steroids segment held the largest share of the market. The anti-seizure segment is expected to register the fastest CAGR of 6.2% during the forecast period.  

Distribution Channel-Based Insights

Based on distribution channel, the chemotherapy induced peripheral neuropathy market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2021, the hospital pharmacy segment held the largest share of the market. Further, the retail pharmacy segment is expected to report the highest CAGR of 5.9% during 2021–2028.

The chemotherapy induced peripheral neuropathy (CIPN) market players focus on adopting organic strategies such as product launch and expansion to expand their footprint and product portfolio worldwide, as well as to meet the growing demands.

Chemotherapy Induced Peripheral Neuropathy Market Report Scope

By Geography

Based on geography, the chemotherapy induced peripheral neuropathy market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Company Profiles

• Regenacy Pharmaceuticals, Inc.
• Asahi Kasei Pharma Corporation
• Novaremed
• Makscientific, Llc
• Wex Pharmaceuticals Inc.
• Sova Pharmaceuticals, Inc.
• Kineta, Inc.
• Aptinyx Inc.
• Apexian Pharmaceuticals, Inc.
• Winsantor, Inc.    

Chemotherapy Induced Peripheral Neuropathy Report Scope